title: Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on atrial fibrillation.
abstract: OBJECTIVE
  To gain insight in the prognosis and treatment of atrial fibrillation (AF) patients during 1-year follow-up in the Euro Heart Survey (EHS) on AF.
  
  
  RESULTS
  The EHS enrolled 5333 AF patients in 2003--2004. One-year follow-up data were available for 80%. Of first detected AF patients, 46% did not have a recurrence during 1 year, paroxysmal AF largely remained paroxysmal AF (80%), and 30% of persistent AF progressed to permanent AF. Many treatment changes occurred since baseline. Oral anticoagulation was started in 19% and discontinued in 16% of all patients. Of patients initially on rhythm control 27% did not receive rhythm control during follow-up, whereas 15% of patients initially on rate control received rhythm control. Mortality was highest in permanent AF (8.2%), but also substantial in first detected AF (5.7%). In multivariable analysis, sinus rhythm at baseline was associated with lower mortality, but no significant effect was observed regarding the application of either rhythm or rate control.
  
  
  CONCLUSIONS
  The EHS on AF provides unique prospective observational data on AF progression, long-term treatment, prognosis, and determinants of adverse outcome of the total clinical spectrum of AF in a European cardiology-based patient cohort.
authors.affiliation: Department of Cardiology, University Hospital Maastricht, Maastricht, The Netherlands. nieuwlaatrobby@live.com.au
authors.forename: Robby
authors.initials: R
authors.lastname: Nieuwlaat
authors.forename: Martin H
authors.initials: MH
authors.lastname: Prins
authors.forename: Jean-Yves
authors.initials: JY
authors.lastname: Le Heuzey
authors.forename: Panos E
authors.initials: PE
authors.lastname: Vardas
authors.forename: Etienne
authors.initials: E
authors.lastname: Aliot
authors.forename: Massimo
authors.initials: M
authors.lastname: Santini
authors.forename: Stuart M
authors.initials: SM
authors.lastname: Cobbe
authors.forename: Jos W M G
authors.initials: JW
authors.lastname: Widdershoven
authors.forename: Leo H
authors.initials: LH
authors.lastname: Baur
authors.forename: Samuel
authors.initials: S
authors.lastname: Lévy
authors.forename: Harry J G M
authors.initials: HJ
authors.lastname: Crijns
mesh_terms: D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000188:drug therapy / Q000401:mortality*; D018450:Disease Progression; D004562:Electrocardiography / Q000379:methods; D005260:Female; D006331:Heart Diseases / Q000188:drug therapy / Q000401:mortality; D006470:Hemorrhage / Q000188:drug therapy / Q000401:mortality*; D006801:Humans; D008297:Male; D011379:Prognosis; D011446:Prospective Studies; D018570:Risk Assessment; D020521:Stroke / Q000150:complications*; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D000925:Anticoagulants